Xencor is developing superior monoclonal antibody therapeutics that have been optimized to treat autoimmune disorders, asthma and allergic diseases, and cancer. Currently, eight candidates that have been engineered with Xencor’s XmAb® technology are in clinical development internally and with partners. Xencor’s internally-discovered programs include: XmAb®5871 in a Phase 1b/2a clinical trial for the treatment of rheumatoid arthritis and in preparation for a clinical trial in IgG4-related disease; XmAb®7195 in Phase 1a development for the treatment of asthma; and XmAb®5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Our XmAb® antibody engineering platform enables us to make subtle changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action, and enhanced performance and market differentiation. These small structural changes augment the interactions that antibodies naturally have with the immune system. We have created a set of enhancements that allow us to increase immune inhibitory activity, extend circulating half-life or enhance cytotoxicity while maintaining 99.5% identity in structure and sequence to natural antibodies. We thereby can avoid the product development challenges of many other next-generation biologics because XmAb antibodies retain the natural antibody structure. Our XmAb technology fuels the growth of our internal pipeline and generates revenues through partnering and licensing.